Related Experiment Video
Updated: Aug 17, 2025
09:23
Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles "Nanoblades"
Published on: March 31, 2021
5.1K
Holding it together: Nanoparticle stabilization of LASV trimer
1Paul G. Allen School of Global Health, Washington State University, Pullman, WA, USA.
Cell Host & Microbe
|December 15, 2022
Summary
Developing Lassa virus (LASV) vaccines is difficult because recombinant immunogens are unstable. A new nanoparticle strategy successfully stabilized the LASV glycoprotein complex, inducing broadly neutralizing antibodies for improved vaccine potential.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Lassa virus (LASV) poses a significant public health threat, necessitating effective vaccine strategies.
- The development of LASV vaccines has been hindered by the instability of recombinant immunogens, particularly the glycoprotein complex (GPC).
Purpose of the Study:
- To overcome the instability of LASV recombinant immunogens.
- To develop a vaccine strategy that elicits broadly neutralizing antibodies against LASV.
Main Methods:
- Utilized a two-component nanoparticle system for antigen presentation.
- Engineered stable trimeric forms of the LASV glycoprotein complex (GPC).
Main Results:
- Achieved stable trimeric presentation of the LASV GPC on nanoparticles.
- Demonstrated the induction of broadly neutralizing antibodies in response to the nanoparticle-based immunogen.
Conclusions:
- The two-component nanoparticle strategy offers a promising approach for developing stable LASV vaccine candidates.
- This method enables the presentation of a functional GPC, leading to the generation of protective immune responses.
